First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817
Neal E Ready, Clarisse Audigier-Valette, Jonathan W Goldman, Enriqueta Felip, Tudor-Eliade Ciuleanu, María Rosario García Campelo, Kevin Jao, Fabrice Barlesi, Stéphanie Bordenave, Erika Rijavec, Laszlo Urban, Jean-Sébastien Aucoin, Cristina Zannori, Karim Vermaelen, Osvaldo Arén Frontera, Alessandra Curioni Fontecedro, Amparo Sánchez-Gastaldo, Oscar Juan-Vidal, Helena Linardou, Elena Poddubskaya, David R Spigel, Samreen Ahmed, Michele Maio, Sunney Li, Han Chang, Joseph Fiore, Angelic Acevedo, Luis Paz-Ares
Journal for ImmunoTherapy of Cancer Feb 2023, 11 (2) e006127; DOI: 10.1136/jitc-2022-006127